| Name | Title | Contact Details |
|---|
The Big O Tires story begins back in 1962, just as Americas new love affair with the automobile was hitting high gear. The market for replacement tires was exploding, and independent tire dealers found themselves struggling to compete in the face of low prices offered by major tire manufacturers own company stores. Big Os founding fathers were a handful of progressive independent tire dealers who decided to band together to form a tire-buying cooperative so that they could secure volume pricing and keep their customers happy. Their concept worked. In the years that followed, The Big O Tires co-op evolved into a full-fledged franchise as it continued to find innovative ways to harness the power of the collective to benefit independent dealerships and their customers. Almost a half-decade later, Big O Tires has become North Americas largest retail tire franchisor, with over 400 independently-owned and operated locations in 20 states, providing customers with a broad range of automotive services in addition to quality tires, wheels and accessories. Big O has become an industry role model admired for its innovative approach to franchising and unmatched customer loyalty ratings. In 1996, Big O Tires joined forces with one of the largest and most respected tire marketers in the nation when it became part of the TBC Retail Group, an automotive retail network comprised of some 1,200 Big O Tires, Tire Kingdom, Merchants and NTB locations spanning 40 U.S. states. Big Os reach was broadened again in 2005, when TBC Corporation was acquired by Sumitomo Corporation of America, the largest wholly-owned subsidiary of Tokyo-based Sumitomo, one of the worlds leading traders of goods and services. As Big O Tires continues to thrive and adapt to an ever-changing marketplace, it remains rooted in its humble beginnings as a proud collective of independent dealers committed to putting its customers first.
Yokohama TWS, part of The Yokohama Rubber Co., Ltd., is a leader in designing and producing tire and wheel solutions to drive a sustainable future for Agriculture, Construction, Material Handling and Two-Wheeler markets. Our 6,600+ workforce on 5 continents, 14 state-of-the-art manufacturing facilities, OEM partnerships, digital technologies, field tests and sustainable product sourcing all work together to bring our customers worldwide the latest in tire innovations and services that enhance their performance and improve their businesses. Combining value, safety and ease, Yokohama TWS offers a multi-brand portfolio which includes the Trelleborg, Mitas, Maximo, and Cultor brands and Interfit custom fitting services. Our brands are supported by a vast network of local specialists, to bring tailor-made services that evolve with our customers and their businesses, wherever they are. We pair localized expertise with the power of our global reach; staying close to the communities and companies where people need us most. Indeed, for Yokohama TWS, fostering a company-wide culture of sustainability focused on planet, innovative products and support for people and places where we operate is simply the right thing to do. We are equally committed to becoming a sustainability leader in our industry. We aim to minimize the impact that our global operations and supply chain has on the environment. And to achieve this, we empower our employees to make a difference. They work as one to drive positive change throughout our company, our products, and our industry. Innovation – Technology – Sustainability – Service – Caring for our communities: Our people take ownership to deliver on this promise every day. This is how, for over a century, Yokohama TWS has and will continue to bring specialty tire and wheel solutions – engineered for the future.
Saber Law Group is women- and minority-owned boutique employment law and litigation firm based in San Francisco. * Saber attorneys hit the ground running with deep bench expertise and diverse backgrounds. * Saber attorneys are like legal, business, and operations strategists all in one. * Saber attorneys are driven by clients long-term success, many of whom have stayed with the team for decades. Our brand of client service is in high demand. Were expanding. How do you know youre ready to join Saber? * FOCUSED – You wont let anything stand in between yourself and your end goal. * INSPIRED – You are moved to practice law beyond a paycheck or a title. * RESILIENT – You have crossed hurdles and done anything to get to the finish line. * SOCIAL – You gather to share battle stories and wins at the finish line. * PREPARED – Youre an intricate planner, and preparation is vital for you. You dont just show up and hope for the best. When you turn up, you will be in prime condition. * BRAVE –The legal profession is one of the toughest. At Saber, you will be celebrated.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.